Market's view on Induction Heal.
Published on April 2024
- Stock watchers anticipate the announcement of an NHS England contract and expect more NHS contracts following the new financial budgets.
- Updates on results and contract wins are expected next week.
- The renewal of NHS England contracts and hospital purchases in April are seen as factors that could double the current stock price by the end of May.
- Induction Healthcare is showcasing a collaborative PEP solution with Oracle Health at the Patient Portal UK (PPUK) during the Oracle Health Collaboration Forum in London.
- The integration of Zesty into NHS systems and updates to the NHS app are significant due to the ongoing demand for remote consultations, with maternity being a new area of adoption.
- The Attend Anywhere platform by Induction has become the system of choice for NHS video consultations across the British Isles, saving significant patient time and costs.
- Recent signings of three new patient portal development contracts totaling £1.4m point to potential for 10+ new contracts this year.
- The stock price has risen significantly, now within the top 75 risers, and is considered very undervalued by some watchers, who foresee a potential rebound to mid-20s prices.
- Historical concerns were raised about the company being massively overvalued, with suggestions that the stock was worth as little as 15p.
- There is confusion about the company’s market capitalisation, which remains high despite a significant drop in share price since its initial public offering.